Exhibit 99.1 NeoGenomics Reports Fourth Quarter and Full Year 2023 Results Fourth Quarter Revenue Increased 12% to $156 million; Full Year Revenue Increased 16% to $592 million Fort Myers, Florida, (February 20, 2024) - NeoGenomics, Inc. (Nasdaq: NEO) (the "Company"), a leading provider of oncology testing and global contract research services, today announced fourth quarter and full year 2023 results for the period ended December 31, 2023. Highlights "NeoGenomics' fourth quarter and full year 2023 results ...

ThirdQuarter 2023 Earnings Results 2 This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdictio ...

财务数据和关键指标变化 - 第三季度收入同比增长18%,达到1.52亿美元 [10][28] - 临床服务收入同比增长20%,主要由于检测量增加和每项检测收入上升 [30] - 高通量测序(NGS)收入同比增长超过35%,占临床收入的25% [10][31] - 调整后毛利率为44.2%,同比提升247个基点 [33] - 调整后EBITDA为300万美元,同比大幅改善129% [11][29] 各条业务线数据和关键指标变化 - 临床服务业务收入同比增长20%,主要由于检测量增加7%和每项检测收入增加12% [30] - 高通量测序(NGS)业务收入占临床收入的比重接近25%,增速远高于市场平均水平 [10][31] - 高级诊断业务(包括制药服务和信息学)收入同比增长8%,增速有所放缓,但毛利率和利润率持续改善 [10][32] 各个市场数据和关键指标变化 - 公司在社区肿瘤医生群体中的渗透度持续提高,有助于各业务线的增长 [67] - 公司在三重阴性乳腺癌领域提交了新的RaDaR适应症申请 [149] 公司战略和发展方向及行业竞争 - 公司继续执行"保护、拓展、收购"的商业策略,推动核心业务的利润增长 [16] - 公司加大对高级诊断业务(包括制药服务和信息学)的创新投入,提升该业务的毛利率和利润率 [18][20] - 公司正在向"癌症检测信息决策支持公司"转型,致力于成为行业领导者 [41] - 公司正在应对FDA对实验室自主研发检测项目(LDT)的新监管政策,有信心应对相关挑战 [24][25] 管理层对经营环境和未来前景的评论 - 管理层对公司在2023年的业务执行和财务表现感到非常满意,并对未来保持乐观态度 [40][41] - 管理层认为公司在提高运营效率、优化成本结构、提升收入质量等方面仍有很大的改善空间 [49][174][177] - 管理层表示公司将继续投资于业务创新和新产品开发,以保持行业领先地位 [19][41] 问答环节重要的提问和回答 问题1 **Vidyun Bais 提问** 询问RaDaR在27个正在进行的临床试验中的关键数据节点 [45] **Vishal Sikri 回答** RaDaR在乳腺癌领域的TRACER临床试验将在本年底有数据发布,其他试验将在2024年陆续有数据结果 [47] 问题2 **Andrew Brackman 提问** 询问公司每项检测收入持续增长的可持续性 [56] **Chris Smith 和 Jeff Sherman 回答** 公司认为未来几年每项检测收入仍有较大增长空间,主要来自于NGS业务占比提升、收费优化和价格调整等多方面因素 [57][58][59][60] 问题3 **David Westenberg 提问** 询问PAMA政策对公司未来业绩的影响 [91] **Warren Stone 回答** PAMA政策主要影响较低附加值的检测项目,对公司整体业绩影响有限 [92][93]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorpora ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorporation ...

财务数据和关键指标变化 - 第二季度收入为1.47亿美元,同比增长18% [9] - 临床服务收入增长17%,主要由于检测量增加和每项检测收入增加 [21] - 高级诊断收入增长22%,主要由于核心制药业务、信息化和RaDaR业务的强劲表现 [22] - 调整后毛利率为44.1%,同比提升505个基点 [24] - 调整后EBITDA为负200万美元,同比改善8700万美元或87% [10] 各条业务线数据和关键指标变化 - 临床服务业务收入增长17%,主要由于检测量增加8%和每项检测收入增加8% [21] - 高级诊断业务收入增长22%,主要由于制药业务、信息化和RaDaR业务的增长 [22] - 公司正在优化高级诊断业务,减少一些小型且不盈利的合同,以提高该业务的盈利能力 [23] 各个市场数据和关键指标变化 - 公司未具体披露各个市场的数据和指标变化 公司战略和发展方向及行业竞争 - 公司提出四大战略重点:发展核心业务、加速高级诊断业务、创造价值、提升人才和文化 [13] - 公司在NGS产品线、RaDaR检测和实验室自动化等方面持续投入和创新,以提升竞争力 [14][15][17][18] - 公司正在优化高级诊断业务,减少一些小型且不盈利的合同,以提高该业务的盈利能力 [23] 管理层对经营环境和未来前景的评论 - 公司对未来保持乐观,认为有很大的改善空间,并提高了全年收入和利润指引 [26][27][28] - 公司认为未来有机会进一步提升毛利率和盈利能力,并将继续投资以把握未来增长机会 [29] 问答环节重要的提问和回答 问题1 **Dan Brennan 提问** 询问公司对2023年下半年和2024年的业务展望,特别是高级诊断业务的情况 [36][37][38][39][40][41] **Chris Smith 和 Vishal Sikri 回答** 公司对临床业务保持乐观,预计下半年增长趋势与上半年相似 高级诊断业务受到去年第四季度强劲表现的影响,以及公司正在优化该业务的一些小型不盈利合同,预计下半年增速会有所放缓,但长期来看仍有很大改善空间 [37][40][43] 问题2 **Alex Nowak 提问** 询问RaDaR乳腺癌适应症获得Medicare报销后,公司如何获取5年后无活动疾病患者的样本,以及未来其他适应症的申报计划 [59][60][61][62][63] **Vishal Sikri 回答** 公司通过与医院的关系,已经能够获取到所需的样本,并正在积极推进其他适应症的申报工作,计划在年底前提交两个新的适应症和扩展乳腺癌适应症 [61][62][63] 问题3 **Mark Massaro 提问** 询问公司新推出的NGS产品线在第二季度的表现,以及未来大型NGS产品的上市时间 [86][87][88][89][90][91][92][93][94][95] **Vishal Sikri 和 Warren Stone 回答** 公司的NGS产品线包括血液肿瘤和实体瘤两大类,其中血液肿瘤一直保持强劲增长,实体瘤新产品正在快速拓展,公司正在加大研发和销售投入,未来有望推出更大型的NGS产品 [87][88][89][90][91][92][93][94][95]

2 This presentation contains financial measures, such as adjusted EBITDA, adjusted gross margin and adjusted net income, which are considered non-GAAP financial measures under applicable U.S. Securities and Exchange Commission rules and regulations. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP). Adjusted EBITDA, adjusted gross margin and adjusted net inco ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorporation ...

NeoGenomics, Inc. (NASDAQ:NEO) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Kendra Sweeney - VP of IR Chris Smith - CEO Jeff Sherman - CFO Warren Stone - President of Clinical Service Division Vishal Sikri - President of Advanced Diagnostics Division Melody Harris - President of Enterprise Operations Conference Call Participants Puneet Souda - SVB Securities David Westenberg - Piper Sandler Dan Brennan - TD Cowen Andrew Brackmann - William Blair David Delahunt - Goldman Sachs ...

2 1st Quarter Clinical Services Revenue per Test • 8th Consecutive Quarter of Revenue per Test Growth • Revenue per Test Increased 8% over Prior Year to $402 • Focused on Higher-Value Tests • Positive Contributions from Strategic Reimbursement Initiatives Q2 Q3 Q4 Q1 • Gross Margin Improved 620 bps, representing the Third Consecutive Quarter of 500 bps+ of Improvement • Revenue: Highest Revenue Growth by Quarter Since Q2 of 2021. Drivers are increases in revenue per test, volume and Pharma Services revenue. ...